GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 58 Thousand USD | -66.67% |
| 2022 | 174 Thousand USD | 461.29% |
| 2021 | 31 Thousand USD | -99.88% |
| 2020 | 26.33 Million USD | 97.14% |
| 2019 | 13.35 Million USD | 23.64% |
| 2018 | 10.8 Million USD | 34751.61% |
| 2017 | 31 Thousand USD | -99.75% |
| 2016 | 12.41 Million USD | 27.35% |
| 2015 | 9.74 Million USD | 190.18% |
| 2014 | 3.35 Million USD | 29.79% |
| 2013 | 2.58 Million USD | 37.66% |
| 2012 | 1.88 Million USD | -8.78% |
| 2011 | 2.06 Million USD | -4.76% |
| 2010 | 2.16 Million USD | 1.84% |
| 2009 | 2.12 Million USD | -1.07% |
| 2008 | 2.14 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 3.18 Million USD | 4.05% |
| 2005 | 3.06 Million USD | 125.0% |
| 2004 | 1.36 Million USD | 750.0% |
| 2003 | 160 Thousand USD | 0.0% |
| 2002 | 160 Thousand USD | -37.01% |
| 2001 | 254 Thousand USD | -37.9% |
| 2000 | 409 Thousand USD | -57.79% |
| 1999 | 969 Thousand USD | -59.63% |
| 1998 | 2.4 Million USD | -22.58% |
| 1997 | 3.1 Million USD | 138.46% |
| 1996 | 1.3 Million USD | -59.38% |
| 1995 | 3.2 Million USD | 190.91% |
| 1994 | 1.1 Million USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| 1989 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - USD | -100.0% |
| 2024 Q1 | 30 Thousand USD | -48.28% |
| 2023 Q4 | 58 Thousand USD | -36.96% |
| 2023 Q2 | 120 Thousand USD | -18.37% |
| 2023 Q1 | 147 Thousand USD | -15.52% |
| 2023 Q3 | 92 Thousand USD | -23.33% |
| 2023 FY | 58 Thousand USD | -66.67% |
| 2022 Q1 | 247 Thousand USD | 696.77% |
| 2022 Q3 | 198 Thousand USD | -11.21% |
| 2022 Q2 | 223 Thousand USD | -9.72% |
| 2022 Q4 | 174 Thousand USD | -12.12% |
| 2022 FY | 174 Thousand USD | 461.29% |
| 2021 Q4 | 31 Thousand USD | 0.0% |
| 2021 FY | 31 Thousand USD | -99.88% |
| 2021 Q2 | 31 Thousand USD | 0.0% |
| 2021 Q1 | 31 Thousand USD | -99.88% |
| 2021 Q3 | 31 Thousand USD | 0.0% |
| 2020 Q2 | 21.96 Million USD | 64.0% |
| 2020 Q1 | 13.39 Million USD | 0.26% |
| 2020 Q3 | 23.11 Million USD | 5.23% |
| 2020 Q4 | 26.33 Million USD | 13.94% |
| 2020 FY | 26.33 Million USD | 97.14% |
| 2019 Q4 | 13.35 Million USD | 0.38% |
| 2019 Q1 | 11.48 Million USD | 6.34% |
| 2019 FY | 13.35 Million USD | 23.64% |
| 2019 Q2 | 12.34 Million USD | 7.48% |
| 2019 Q3 | 13.3 Million USD | 7.77% |
| 2018 Q4 | 10.8 Million USD | 1.66% |
| 2018 Q3 | 10.62 Million USD | 54.32% |
| 2018 Q2 | 6.88 Million USD | 132.43% |
| 2018 Q1 | 2.96 Million USD | 9458.06% |
| 2018 FY | 10.8 Million USD | 34751.61% |
| 2017 FY | 31 Thousand USD | -99.75% |
| 2017 Q1 | 11.79 Million USD | -5.0% |
| 2017 Q3 | 31 Thousand USD | -99.75% |
| 2017 Q2 | 12.41 Million USD | 5.32% |
| 2017 Q4 | 31 Thousand USD | 0.0% |
| 2016 FY | 12.41 Million USD | 27.35% |
| 2016 Q3 | 11.29 Million USD | 6.51% |
| 2016 Q2 | 10.6 Million USD | 0.21% |
| 2016 Q1 | 10.57 Million USD | 8.54% |
| 2016 Q4 | 12.41 Million USD | 9.94% |
| 2015 Q4 | 9.74 Million USD | 59.84% |
| 2015 FY | 9.74 Million USD | 190.18% |
| 2015 Q1 | 3.75 Million USD | 11.88% |
| 2015 Q2 | 4.4 Million USD | 17.14% |
| 2015 Q3 | 6.09 Million USD | 38.53% |
| 2014 Q2 | 2.82 Million USD | 3.63% |
| 2014 Q1 | 2.72 Million USD | 5.29% |
| 2014 Q4 | 3.35 Million USD | 11.52% |
| 2014 Q3 | 3.01 Million USD | 6.66% |
| 2014 FY | 3.35 Million USD | 29.79% |
| 2013 Q3 | 2.27 Million USD | 4.75% |
| 2013 Q1 | 1.92 Million USD | 2.39% |
| 2013 Q2 | 2.16 Million USD | 12.57% |
| 2013 Q4 | 2.58 Million USD | 14.01% |
| 2013 FY | 2.58 Million USD | 37.66% |
| 2012 Q3 | 2.68 Million USD | 21.54% |
| 2012 Q4 | 1.88 Million USD | -29.85% |
| 2012 FY | 1.88 Million USD | -8.78% |
| 2012 Q1 | 2.2 Million USD | 6.74% |
| 2012 Q2 | 2.2 Million USD | 0.23% |
| 2011 FY | 2.06 Million USD | -4.76% |
| 2011 Q1 | 2.03 Million USD | -5.82% |
| 2011 Q2 | 2.09 Million USD | 2.75% |
| 2011 Q3 | 198 Thousand USD | -90.54% |
| 2011 Q4 | 2.06 Million USD | 940.91% |
| 2010 FY | 2.16 Million USD | 1.84% |
| 2010 Q4 | 2.16 Million USD | -0.41% |
| 2010 Q3 | 2.17 Million USD | -6.98% |
| 2010 Q2 | 2.33 Million USD | -10.22% |
| 2010 Q1 | 2.6 Million USD | 22.45% |
| 2009 Q1 | 2.15 Million USD | 0.47% |
| 2009 FY | 2.12 Million USD | -1.07% |
| 2009 Q4 | 2.12 Million USD | -7.37% |
| 2009 Q3 | 2.29 Million USD | 4.51% |
| 2009 Q2 | 2.19 Million USD | 1.71% |
| 2008 Q1 | 966 Thousand USD | 0.0% |
| 2008 FY | 2.14 Million USD | 0.0% |
| 2008 Q4 | 2.14 Million USD | 0.23% |
| 2008 Q3 | 2.14 Million USD | 99.53% |
| 2008 Q2 | 1.07 Million USD | 11.18% |
| 2007 Q1 | 290 Thousand USD | -90.89% |
| 2007 FY | - USD | -100.0% |
| 2007 Q3 | 628 Thousand USD | 37.12% |
| 2007 Q2 | 458 Thousand USD | 57.93% |
| 2007 Q4 | - USD | -100.0% |
| 2006 Q4 | 3.18 Million USD | -10.18% |
| 2006 FY | 3.18 Million USD | 4.05% |
| 2006 Q2 | 3.66 Million USD | 0.0% |
| 2006 Q1 | 3.66 Million USD | 19.61% |
| 2006 Q3 | 3.54 Million USD | -3.14% |
| 2005 FY | 3.06 Million USD | 125.0% |
| 2005 Q4 | 3.06 Million USD | 0.0% |
| 2005 Q1 | 160 Thousand USD | -88.24% |
| 2005 Q2 | - USD | -100.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q3 | 1.76 Million USD | 8.82% |
| 2004 FY | 1.36 Million USD | 750.0% |
| 2004 Q1 | 279 Thousand USD | 74.38% |
| 2004 Q4 | 1.36 Million USD | -22.9% |
| 2004 Q2 | 1.62 Million USD | 481.0% |
| 2003 Q2 | 160 Thousand USD | 0.0% |
| 2003 Q1 | 160 Thousand USD | 0.0% |
| 2003 FY | 160 Thousand USD | 0.0% |
| 2003 Q3 | 160 Thousand USD | 0.0% |
| 2003 Q4 | 160 Thousand USD | 0.0% |
| 2002 Q1 | 207 Thousand USD | -18.5% |
| 2002 FY | 160 Thousand USD | -37.01% |
| 2002 Q4 | 160 Thousand USD | -3.61% |
| 2002 Q3 | 166 Thousand USD | -8.29% |
| 2002 Q2 | 181 Thousand USD | -12.56% |
| 2001 Q1 | 402 Thousand USD | -1.71% |
| 2001 FY | 254 Thousand USD | -37.9% |
| 2001 Q4 | 254 Thousand USD | -10.56% |
| 2001 Q3 | 284 Thousand USD | -37.03% |
| 2001 Q2 | 451 Thousand USD | 12.19% |
| 2000 Q3 | 701 Thousand USD | -1.13% |
| 2000 Q4 | 409 Thousand USD | -41.65% |
| 2000 Q2 | 709 Thousand USD | -2.88% |
| 2000 FY | 409 Thousand USD | -57.79% |
| 2000 Q1 | 730 Thousand USD | -24.66% |
| 1999 Q3 | 900 Thousand USD | -10.0% |
| 1999 Q2 | 1 Million USD | 0.0% |
| 1999 Q1 | 1 Million USD | -58.33% |
| 1999 Q4 | 969 Thousand USD | 7.67% |
| 1999 FY | 969 Thousand USD | -59.63% |
| 1998 Q4 | 2.4 Million USD | 0.0% |
| 1998 FY | 2.4 Million USD | -22.58% |
| 1998 Q3 | 2.4 Million USD | -11.11% |
| 1998 Q1 | 3.2 Million USD | 3.23% |
| 1998 Q2 | 2.7 Million USD | -15.63% |
| 1997 Q4 | 3.1 Million USD | 158.33% |
| 1997 Q3 | 1.2 Million USD | 0.0% |
| 1997 Q2 | 1.2 Million USD | -20.0% |
| 1997 Q1 | 1.5 Million USD | 15.38% |
| 1997 FY | 3.1 Million USD | 138.46% |
| 1996 FY | 1.3 Million USD | -59.38% |
| 1996 Q2 | 500 Thousand USD | -84.38% |
| 1996 Q4 | 1.3 Million USD | 225.0% |
| 1996 Q3 | 400 Thousand USD | -20.0% |
| 1996 Q1 | 3.2 Million USD | 0.0% |
| 1995 Q1 | 1.7 Million USD | 54.55% |
| 1995 FY | 3.2 Million USD | 190.91% |
| 1995 Q3 | 2.1 Million USD | -8.7% |
| 1995 Q4 | 3.2 Million USD | 52.38% |
| 1995 Q2 | 2.3 Million USD | 35.29% |
| 1994 FY | 1.1 Million USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q4 | 1.1 Million USD | 10.0% |
| 1994 Q3 | 1 Million USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adaptive Biotechnologies Corporation | 229.43 Million USD | 99.975% |
| IO Biotech, Inc. | 2.49 Million USD | 97.674% |
| VYNE Therapeutics Inc. | 214 Thousand USD | 72.897% |
| Organovo Holdings, Inc. | 1.39 Million USD | 95.839% |
| TNF Pharmaceuticals, Inc. | 48.87 Thousand USD | -18.682% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | 64.627% |
| Tonix Pharmaceuticals Holding Corp. | 9.81 Million USD | 99.409% |
| Aadi Bioscience, Inc. | 7.02 Million USD | 99.174% |
| Savara Inc. | 26.73 Million USD | 99.783% |
| Aerovate Therapeutics, Inc. | 675 Thousand USD | 91.407% |
| Rocket Pharmaceuticals, Inc. | 25.04 Million USD | 99.768% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 99.722% |
| ZyVersa Therapeutics, Inc. | 8656.00 USD | -570.055% |
| Soligenix, Inc. | 3.49 Million USD | 98.34% |
| Aptose Biosciences Inc. | 1 Million USD | 94.256% |
| NKGen Biotech, Inc. Common Stock | 19.92 Million USD | 99.709% |
| Century Therapeutics, Inc. | 48.17 Million USD | 99.88% |
| Eterna Therapeutics Inc. | 41.84 Million USD | 99.861% |
| Precision BioSciences, Inc. | 31.26 Million USD | 99.815% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 99.969% |
| Kura Oncology, Inc. | 17.2 Million USD | 99.663% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Dyadic International, Inc. | 136.92 Thousand USD | 57.642% |
| TScan Therapeutics, Inc. | 92.43 Million USD | 99.937% |
| IDEAYA Biosciences, Inc. | 2.87 Million USD | 97.981% |
| CytomX Therapeutics, Inc. | 13.97 Million USD | 99.585% |
| Autolus Therapeutics plc | 52.96 Million USD | 99.89% |
| Eton Pharmaceuticals, Inc. | 5.45 Million USD | 98.937% |
| EyePoint Pharmaceuticals, Inc. | 5.46 Million USD | 98.939% |
| GRI Bio, Inc. | 14 Thousand USD | -314.286% |
| Tenaya Therapeutics, Inc. | 12.42 Million USD | 99.533% |
| IGM Biosciences, Inc. | 40.5 Million USD | 99.857% |
| Heron Therapeutics, Inc. | 179.62 Million USD | 99.968% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | 99.018% |
| Entero Therapeutics, Inc. | 826.84 Thousand USD | 92.985% |
| Opthea Limited | 200.62 Million USD | 99.971% |
| X4 Pharmaceuticals, Inc. | 58.28 Million USD | 99.9% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 99.9% |
| Pliant Therapeutics, Inc. | 11.37 Million USD | 99.49% |
| Ligand Pharmaceuticals Incorporated | 6.16 Million USD | 99.059% |
| Surrozen, Inc. | 3.37 Million USD | 98.284% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 3.13 Million USD | 98.15% |
| Ovid Therapeutics Inc. | 46 Million USD | 99.874% |
| Sorrento Therapeutics, Inc. | 134.5 Million USD | 99.957% |
| Acelyrin, Inc. | 1.19 Million USD | 95.142% |
| Centessa Pharmaceuticals plc | 84.58 Million USD | 99.931% |
| Hepion Pharmaceuticals, Inc. | 209.02 Thousand USD | 72.251% |
| Arcturus Therapeutics Holdings Inc. | 30.21 Million USD | 99.808% |
| Syros Pharmaceuticals, Inc. | 62.07 Million USD | 99.907% |
| ADMA Biologics, Inc. | 141.41 Million USD | 99.959% |
| PureTech Health plc | 25.51 Million USD | 99.773% |
| Oncternal Therapeutics, Inc. | 318 Thousand USD | 81.761% |
| FibroBiologics, Inc. Common Stock | 1.74 Million USD | 96.68% |
| Barinthus Biotherapeutics plc | 12.97 Million USD | 99.553% |
| Kymera Therapeutics, Inc. | 84.67 Million USD | 99.932% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 247 Thousand USD | 76.518% |
| ChromaDex Corporation | 3.27 Million USD | 98.23% |
| Inhibikase Therapeutics, Inc. | 622 Thousand USD | 90.675% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 189.94 Million USD | 99.969% |
| Akebia Therapeutics, Inc. | 104.18 Million USD | 99.944% |
| Better Therapeutics, Inc. | 14.88 Million USD | 99.61% |
| Nurix Therapeutics, Inc. | 30.61 Million USD | 99.811% |
| Apellis Pharmaceuticals, Inc. | 110.92 Million USD | 99.948% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 99.848% |
| Seer, Inc. | 28.25 Million USD | 99.795% |
| Aridis Pharmaceuticals, Inc. | 6.13 Million USD | 99.054% |
| LAVA Therapeutics N.V. | 6.31 Million USD | 99.081% |
| Gritstone bio, Inc. | 104.77 Million USD | 99.945% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | 97.918% |
| Avid Bioservices, Inc. | 207.83 Million USD | 99.972% |
| Insmed Incorporated | 1.2 Billion USD | 99.995% |
| Panbela Therapeutics, Inc. | 5.19 Million USD | 98.883% |
| Avalo Therapeutics, Inc. | 3.9 Million USD | 98.514% |
| Fate Therapeutics, Inc. | 103.53 Million USD | 99.944% |
| MediWound Ltd. | 6.71 Million USD | 99.136% |
| BioXcel Therapeutics, Inc. | 101.38 Million USD | 99.943% |
| Fortress Biotech, Inc. | 88.59 Million USD | 99.935% |
| OmniAb, Inc. | 25.56 Million USD | 99.773% |
| Seres Therapeutics, Inc. | 213.93 Million USD | 99.973% |
| Zai Lab Limited | 15.15 Million USD | 99.617% |
| Revance Therapeutics, Inc. | 478.43 Million USD | 99.988% |
| Tarsus Pharmaceuticals, Inc. | 31.73 Million USD | 99.817% |
| Veracyte, Inc. | 12.63 Million USD | 99.541% |
| Abeona Therapeutics Inc. | 5.4 Million USD | 98.926% |
| FibroGen, Inc. | 170.45 Million USD | 99.966% |
| Apogee Therapeutics, Inc. | 2.03 Million USD | 97.148% |
| ContextLogic Inc. | 6 Million USD | 99.033% |
| Intensity Therapeutics, Inc. | 158 Thousand USD | 63.291% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| HOOKIPA Pharma Inc. | 6.55 Million USD | 99.116% |
| Jazz Pharmaceuticals plc | 5.79 Billion USD | 99.999% |
| Entrada Therapeutics, Inc. | 68.23 Million USD | 99.915% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -56.757% |
| ImmuCell Corporation | 11.96 Million USD | 99.515% |
| Fortrea Holdings Inc. | 1.67 Billion USD | 99.997% |
| KalVista Pharmaceuticals, Inc. | 7.31 Million USD | 99.207% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | 97.918% |
| Foghorn Therapeutics Inc. | 45.07 Million USD | 99.871% |
| Ultragenyx Pharmaceutical Inc. | 43.16 Million USD | 99.866% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 99.872% |
| Metagenomi, Inc. Common Stock | 48.22 Million USD | 99.88% |
| Vaxxinity, Inc. | 15.16 Million USD | 99.618% |
| BioCryst Pharmaceuticals, Inc. | 848.71 Million USD | 99.993% |
| Gain Therapeutics, Inc. | 1.02 Million USD | 94.355% |
| Creative Medical Technology Holdings, Inc. | 14.19 Thousand USD | -308.623% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| CASI Pharmaceuticals, Inc. | 21.23 Million USD | 99.727% |
| Senti Biosciences, Inc. | 37.66 Million USD | 99.846% |
| BioRestorative Therapies, Inc. | 162.31 Thousand USD | 64.267% |
| Apollomics, Inc. | 4.66 Million USD | 98.756% |
| 89bio, Inc. | 27.1 Million USD | 99.786% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | 99.95% |
| TransCode Therapeutics, Inc. | 450.57 Thousand USD | 87.127% |
| RAPT Therapeutics, Inc. | 6.9 Million USD | 99.16% |
| Ardelyx, Inc. | 55.98 Million USD | 99.896% |
| Pluri Inc. | 29.61 Million USD | 99.804% |
| Prothena Corporation plc | 11.83 Million USD | 99.51% |
| Pulmatrix, Inc. | 8.75 Million USD | 99.338% |
| Celularity Inc. | 65.41 Million USD | 99.911% |
| MeiraGTx Holdings plc | 89.26 Million USD | 99.935% |
| Omeros Corporation | 338.28 Million USD | 99.983% |
| Ainos, Inc. | 5.96 Million USD | 99.027% |
| Humacyte, Inc. | 58.1 Million USD | 99.9% |
| Mesoblast Limited | 118.92 Million USD | 99.951% |
| Cocrystal Pharma, Inc. | 1.85 Million USD | 96.87% |
| Cidara Therapeutics, Inc. | 4.87 Million USD | 98.811% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.993% |
| Cabaletta Bio, Inc. | 5.01 Million USD | 98.844% |
| Summit Therapeutics Inc. | 106.09 Million USD | 99.945% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Scholar Rock Holding Corporation | 61.81 Million USD | 99.906% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 99.95% |
| Adlai Nortye Ltd. American Depositary Shares | 31.54 Million USD | 99.816% |
| Cytokinetics, Incorporated | 755.77 Million USD | 99.992% |
| Eloxx Pharmaceuticals, Inc. | 13.38 Million USD | 99.567% |
| Nutriband Inc. | 241.28 Thousand USD | 75.962% |
| Protara Therapeutics, Inc. | 5.46 Million USD | 98.939% |
| Roivant Sciences Ltd. | 499.74 Million USD | 99.988% |
| Evogene Ltd. | 1.13 Million USD | 94.903% |
| Applied Therapeutics, Inc. | 1.22 Million USD | 95.269% |
| Hoth Therapeutics, Inc. | 55.16 Thousand USD | -5.139% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.997% |
| BioLineRx Ltd. | 11.59 Million USD | 99.5% |
| Atai Life Sciences N.V. | 16.47 Million USD | 99.648% |
| VistaGen Therapeutics, Inc. | 2.12 Million USD | 97.264% |
| Aurinia Pharmaceuticals Inc. | 97.6 Million USD | 99.941% |
| MediciNova, Inc. | 215.92 Thousand USD | 73.139% |
| Praxis Precision Medicines, Inc. | 2.49 Million USD | 97.675% |
| MiMedx Group, Inc. | 48.09 Million USD | 99.879% |
| PTC Therapeutics, Inc. | 415.02 Million USD | 99.986% |
| Cullinan Oncology, Inc. | 3.59 Million USD | 98.384% |
| Syndax Pharmaceuticals, Inc. | 1.63 Million USD | 96.453% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | 28.991% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | 99.367% |
| 4D Molecular Therapeutics, Inc. | 14.67 Million USD | 99.605% |
| Dyne Therapeutics, Inc. | 27.41 Million USD | 99.788% |
| Kiniksa Pharmaceuticals, Ltd. | 12.25 Million USD | 99.527% |
| Ventyx Biosciences, Inc. | 12.5 Million USD | 99.536% |
| Allakos Inc. | 41.46 Million USD | 99.86% |
| Fulcrum Therapeutics, Inc. | 10.82 Million USD | 99.464% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | 61.589% |
| BioAtla, Inc. | 2.46 Million USD | 97.642% |
| Allogene Therapeutics, Inc. | 95.12 Million USD | 99.939% |
| Larimar Therapeutics, Inc. | 5.54 Million USD | 98.954% |
| Precigen, Inc. | 7.09 Million USD | 99.183% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| XOMA Corporation | 124.45 Million USD | 99.953% |
| Kezar Life Sciences, Inc. | 18.93 Million USD | 99.694% |
| Incyte Corporation | 38.28 Million USD | 99.849% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 99.866% |
| Aligos Therapeutics, Inc. | 11.13 Million USD | 99.479% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 238.63 Million USD | 99.976% |
| Akero Therapeutics, Inc. | 26.04 Million USD | 99.777% |
| Eliem Therapeutics, Inc. | 349 Thousand USD | 83.381% |
| EyeGate Pharmaceuticals, Inc. | 326.49 Thousand USD | 82.235% |
| UroGen Pharma Ltd. | 100.21 Million USD | 99.942% |
| Sutro Biopharma, Inc. | 182.74 Million USD | 99.968% |
| ZIVO Bioscience, Inc. | 346.34 Thousand USD | 83.254% |
| Lisata Therapeutics, Inc. | 305 Thousand USD | 80.984% |
| Stoke Therapeutics, Inc. | 6.83 Million USD | 99.151% |
| Chimerix, Inc. | 2.14 Million USD | 97.295% |
| Outlook Therapeutics, Inc. | 35.55 Million USD | 99.837% |
| 60 Degrees Pharmaceuticals, Inc. | 172.67 Thousand USD | 66.41% |
| Enanta Pharmaceuticals, Inc. | 26.51 Million USD | 99.781% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Portage Biotech Inc. | 47 Thousand USD | -23.404% |
| OncoCyte Corporation | 2.86 Million USD | 97.978% |
| Qualigen Therapeutics, Inc. | 1.29 Million USD | 95.536% |
| Cadrenal Therapeutics, Inc. Common Stock | 21.35 Thousand USD | -171.663% |
| Processa Pharmaceuticals, Inc. | 150.55 Thousand USD | 61.476% |
| Purple Biotech Ltd. | 351 Thousand USD | 83.476% |
| NextCure, Inc. | 6.6 Million USD | 99.122% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Generation Bio Co. | 97.89 Million USD | 99.941% |
| Neumora Therapeutics, Inc. Common Stock | 5.23 Million USD | 98.891% |
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 99.975% |
| TRACON Pharmaceuticals, Inc. | 968 Thousand USD | 94.008% |
| NLS Pharmaceutics AG | 1.63 Million USD | 96.45% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Novavax, Inc. | 280.63 Million USD | 99.979% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| Curis, Inc. | 2.79 Million USD | 97.924% |
| Daré Bioscience, Inc. | 5.31 Million USD | 98.909% |
| Titan Pharmaceuticals, Inc. | 565 Thousand USD | 89.735% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bicycle Therapeutics plc | 44.95 Million USD | 99.871% |
| BeiGene, Ltd. | 930.18 Million USD | 99.994% |
| Kiromic BioPharma, Inc. | 15.54 Million USD | 99.627% |
| Alector, Inc. | 38.91 Million USD | 99.851% |
| Protagonist Therapeutics, Inc. | 1.14 Million USD | 94.917% |
| Erasca, Inc. | 55.85 Million USD | 99.896% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Aura Biosciences, Inc. | 19.55 Million USD | 99.703% |
| Viracta Therapeutics, Inc. | 25.55 Million USD | 99.773% |
| Chemomab Therapeutics Ltd. | 392 Thousand USD | 85.204% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.995% |
| Histogen Inc. | 4.62 Million USD | 98.745% |
| Fortress Biotech, Inc. | 88.59 Million USD | 99.935% |
| Avidity Biosciences, Inc. | 9.85 Million USD | 99.411% |
| Lyell Immunopharma, Inc. | 63.16 Million USD | 99.908% |
| Galecto, Inc. | 249 Thousand USD | 76.707% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.991% |
| Phathom Pharmaceuticals, Inc. | 139.03 Million USD | 99.958% |
| Molecular Templates, Inc. | 12.23 Million USD | 99.526% |
| PDS Biotechnology Corporation | 23.85 Million USD | 99.757% |
| Amylyx Pharmaceuticals, Inc. | 4.23 Million USD | 98.631% |
| Amarin Corporation plc | 8.73 Million USD | 99.336% |
| TG Therapeutics, Inc. | 110.79 Million USD | 99.948% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 98.925% |
| Celldex Therapeutics, Inc. | 2.54 Million USD | 97.718% |
| Cogent Biosciences, Inc. | 18.85 Million USD | 99.692% |
| Onconetix, Inc. | 9.88 Million USD | 99.413% |
| MacroGenics, Inc. | 33.97 Million USD | 99.829% |
| Y-mAbs Therapeutics, Inc. | 1.41 Million USD | 95.913% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Adagene Inc. | 22.3 Million USD | 99.74% |
| Inhibrx Biosciences, Inc. | 210.14 Million USD | 99.972% |
| Cartesian Therapeutics, Inc. | 10.95 Million USD | 99.471% |
| Voyager Therapeutics, Inc. | 20.29 Million USD | 99.714% |
| SciSparc Ltd. | 76 Thousand USD | 23.684% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.929% |
| Astria Therapeutics, Inc. | 329 Thousand USD | 82.371% |
| Black Diamond Therapeutics, Inc. | 25.29 Million USD | 99.771% |
| Arcutis Biotherapeutics, Inc. | 205.91 Million USD | 99.972% |
| Relay Therapeutics, Inc. | 53.46 Million USD | 99.892% |
| Alnylam Pharmaceuticals, Inc. | 2.68 Billion USD | 99.998% |
| Psyence Biomedical Ltd. | 7.65 Million USD | 99.243% |
| Artelo Biosciences, Inc. | 63 Thousand USD | 7.937% |
| 2seventy bio, Inc. | 256.67 Million USD | 99.977% |
| Clene Inc. | 32.16 Million USD | 99.82% |
| Boundless Bio, Inc. Common Stock | 2.19 Million USD | 97.358% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 203.91 Thousand USD | 71.556% |
| Arbutus Biopharma Corporation | 8.72 Million USD | 99.335% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Absci Corporation | 15.95 Million USD | 99.637% |
| XBiotech Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | 17.19 Million USD | 99.663% |
| Lyra Therapeutics, Inc. | 26.88 Million USD | 99.784% |
| Entera Bio Ltd. | 390 Thousand USD | 85.128% |
| Trevena, Inc. | 35.23 Million USD | 99.835% |
| Adaptimmune Therapeutics plc | 25.23 Million USD | 99.77% |
| Caribou Biosciences, Inc. | 27.48 Million USD | 99.789% |
| INmune Bio, Inc. | 10.43 Million USD | 99.444% |
| Citius Pharmaceuticals, Inc. | 481.24 Thousand USD | 87.948% |
| Tyra Biosciences, Inc. | 6.49 Million USD | 99.107% |
| Galmed Pharmaceuticals Ltd. | 41 Thousand USD | -41.463% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 99.785% |
| Tenax Therapeutics, Inc. | 500.9 Thousand USD | 88.421% |
| Jaguar Health, Inc. | 35.86 Million USD | 99.838% |
| Clearside Biomedical, Inc. | 43 Million USD | 99.865% |
| NexImmune, Inc. | 68.8 Thousand USD | 15.709% |
| Connect Biopharma Holdings Limited | 465 Thousand USD | 87.527% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Coeptis Therapeutics Holdings, Inc. | 1.22 Million USD | 95.262% |
| Kronos Bio, Inc. | 28.27 Million USD | 99.795% |
| Innoviva, Inc. | 449.07 Million USD | 99.987% |
| Coherus BioSciences, Inc. | 480.84 Million USD | 99.988% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.998% |
| Bolt Biotherapeutics, Inc. | 20.21 Million USD | 99.713% |
| Verastem, Inc. | 41.55 Million USD | 99.86% |
| ProKidney Corp. | 4.41 Million USD | 98.686% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | 96.27% |
| Imunon, Inc. | 1.62 Million USD | 96.43% |
| Viking Therapeutics, Inc. | 1.26 Million USD | 95.397% |
| Statera Biopharma, Inc. | 16.26 Million USD | 99.643% |
| ImmunityBio, Inc. | 883.67 Million USD | 99.993% |
| Korro Bio, Inc. | 33.2 Million USD | 99.825% |
| Travere Therapeutics, Inc. | 404.78 Million USD | 99.986% |
| Kineta, Inc. | 1.31 Million USD | 95.596% |
| Catalyst Pharmaceuticals, Inc. | 3.55 Million USD | 98.369% |
| Capricor Therapeutics, Inc. | 5.61 Million USD | 98.967% |
| Keros Therapeutics, Inc. | 14.44 Million USD | 99.598% |
| Celularity Inc. | 65.41 Million USD | 99.911% |
| Crinetics Pharmaceuticals, Inc. | 51.72 Million USD | 99.888% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cibus, Inc. | 24.62 Million USD | 99.764% |
| C4 Therapeutics, Inc. | 70.97 Million USD | 99.918% |
| Marinus Pharmaceuticals, Inc. | 110.35 Million USD | 99.947% |
| Eledon Pharmaceuticals, Inc. | 383 Thousand USD | 84.856% |
| Kodiak Sciences Inc. | 181.63 Million USD | 99.968% |
| Sana Biotechnology, Inc. | 104.09 Million USD | 99.944% |
| Annexon, Inc. | 31.35 Million USD | 99.815% |
| Adverum Biotechnologies, Inc. | 75.03 Million USD | 99.923% |
| Assembly Biosciences, Inc. | 2.34 Million USD | 97.523% |
| Elicio Therapeutics, Inc. | 6.91 Million USD | 99.161% |
| Moderna, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | 13.85 Million USD | 99.581% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.996% |
| Vor Biopharma Inc. | 35.66 Million USD | 99.837% |
| Eyenovia, Inc. | 16.1 Million USD | 99.64% |
| DiaMedica Therapeutics Inc. | 400 Thousand USD | 85.5% |
| Puma Biotechnology, Inc. | 111.49 Million USD | 99.948% |
| Monte Rosa Therapeutics, Inc. | 46.03 Million USD | 99.874% |
| Wave Life Sciences Ltd. | 32.11 Million USD | 99.819% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | 94.112% |
| ACADIA Pharmaceuticals Inc. | 57.2 Million USD | 99.899% |
| Immunocore Holdings plc | 84.03 Million USD | 99.931% |
| Tango Therapeutics, Inc. | 38.92 Million USD | 99.851% |
| Galectin Therapeutics Inc. | 71.8 Million USD | 99.919% |
| Alkermes plc | 290.73 Million USD | 99.98% |
| Arcellx, Inc. | 97.62 Million USD | 99.941% |
| Renovaro Biosciences Inc. | 2.45 Million USD | 97.634% |
| Zentalis Pharmaceuticals, Inc. | 45.77 Million USD | 99.873% |
| Sagimet Biosciences Inc. | 65 Thousand USD | 10.769% |
| Regulus Therapeutics Inc. | 3.1 Million USD | 98.13% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | 95.401% |
| Moolec Science SA | 2.64 Million USD | 97.807% |
| Biomea Fusion, Inc. | 10.29 Million USD | 99.437% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Geron Corporation | 85.89 Million USD | 99.932% |
| Mereo BioPharma Group plc | 5.95 Million USD | 99.026% |
| Verrica Pharmaceuticals Inc. | 45.51 Million USD | 99.873% |
| Royalty Pharma plc | 6.13 Billion USD | 99.999% |
| Atea Pharmaceuticals, Inc. | 2.4 Million USD | 97.585% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| Calithera Biosciences, Inc. | 1.66 Million USD | 96.519% |
| TFF Pharmaceuticals, Inc. | 115.25 Thousand USD | 49.676% |
| Mersana Therapeutics, Inc. | 33.83 Million USD | 99.829% |
| Humacyte, Inc. | 58.1 Million USD | 99.9% |
| Structure Therapeutics Inc. | 5.45 Million USD | 98.936% |
| NLS Pharmaceutics AG | 1.63 Million USD | 96.45% |
| Genelux Corporation | 2.51 Million USD | 97.697% |
| ESSA Pharma Inc. | 80.32 Thousand USD | 27.796% |
| aTyr Pharma, Inc. | 15.09 Million USD | 99.616% |
| Notable Labs, Ltd. | 2.04 Million USD | 97.169% |
| Alzamend Neuro, Inc. | 300.71 Thousand USD | 80.713% |
| Mustang Bio, Inc. | 2.49 Million USD | 97.678% |
| Immunovant, Inc. | 138 Thousand USD | 57.971% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | 96.445% |
| Vericel Corporation | 88.14 Million USD | 99.934% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.996% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Vaxcyte, Inc. | 29.22 Million USD | 99.802% |
| Orgenesis Inc. | 22.62 Million USD | 99.744% |
| Spruce Biosciences, Inc. | 4.6 Million USD | 98.742% |
| NeuroBo Pharmaceuticals, Inc. | 203 Thousand USD | 71.429% |
| GH Research PLC | 343 Thousand USD | 83.09% |
| Tempest Therapeutics, Inc. | 20.66 Million USD | 99.719% |
| PepGen Inc. | 20.1 Million USD | 99.712% |
| Moleculin Biotech, Inc. | 574 Thousand USD | 89.895% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | 101 Thousand USD | 42.574% |
| Belite Bio, Inc | 886 Thousand USD | 93.454% |
| Pharming Group N.V. | 171.54 Million USD | 99.966% |
| XOMA Corporation | 124.45 Million USD | 99.953% |
| Reneo Pharmaceuticals, Inc. | 973 Thousand USD | 94.039% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Bionomics Limited | 239.61 Million USD | 99.976% |
| Xencor, Inc. | 83.43 Million USD | 99.93% |
| Replimune Group, Inc. | 75.86 Million USD | 99.924% |
| Pyxis Oncology, Inc. | 21.33 Million USD | 99.728% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Vanda Pharmaceuticals Inc. | 9.4 Million USD | 99.383% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Turnstone Biologics Corp. | 3.21 Million USD | 98.195% |
| Windtree Therapeutics, Inc. | 16.83 Million USD | 99.655% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Olema Pharmaceuticals, Inc. | 2.41 Million USD | 97.6% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | 95.401% |
| Bio-Path Holdings, Inc. | 113 Thousand USD | 48.673% |
| Enlivex Therapeutics Ltd. | 1.03 Million USD | 94.38% |
| CollPlant Biotechnologies Ltd. | 3.15 Million USD | 98.164% |
| scPharmaceuticals Inc. | 40.26 Million USD | 99.856% |
| HilleVax, Inc. | 51.19 Million USD | 99.887% |
| Vera Therapeutics, Inc. | 53.7 Million USD | 99.892% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | 99.361% |
| Immunic, Inc. | 1.33 Million USD | 95.652% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Aptorum Group Limited | 3.36 Million USD | 98.275% |
| Soleno Therapeutics, Inc. | 403 Thousand USD | 85.608% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | 99.361% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Carmell Therapeutics Corporation | 2.13 Million USD | 97.285% |
| Achieve Life Sciences, Inc. | 16.73 Million USD | 99.653% |
| Ocean Biomedical, Inc. | 2.15 Million USD | 97.302% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.987% |
| Salarius Pharmaceuticals, Inc. | 289.64 Thousand USD | 79.975% |
| bluebird bio, Inc. | 330.32 Million USD | 99.982% |
| DBV Technologies S.A. | 14.38 Million USD | 99.597% |
| Compugen Ltd. | 1.35 Million USD | 95.707% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Peak Bio, Inc. | 10.72 Million USD | 99.459% |
| Vincerx Pharma, Inc. | 2.5 Million USD | 97.682% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Sensei Biotherapeutics, Inc. | 6.2 Million USD | 99.066% |
| Orchestra BioMed Holdings, Inc. | 1.68 Million USD | 96.562% |
| Zevra Therapeutics, Inc. | 42.76 Million USD | 99.864% |
| Acrivon Therapeutics, Inc. Common Stock | 4.64 Million USD | 98.751% |
| Benitec Biopharma Inc. | 284 Thousand USD | 79.577% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.931% |
| Adicet Bio, Inc. | 20.92 Million USD | 99.723% |
| Prime Medicine, Inc. | 13.63 Million USD | 99.575% |
| Aditxt, Inc. | 18.21 Million USD | 99.682% |
| Madrigal Pharmaceuticals, Inc. | 117.19 Million USD | 99.951% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 15.3 Million USD | 99.621% |
| GlycoMimetics, Inc. | 808.4 Thousand USD | 92.825% |
| PolyPid Ltd. | 11.77 Million USD | 99.508% |
| Aileron Therapeutics, Inc. | 91.45 Million USD | 99.937% |
| Invivyd, Inc. | 2.16 Million USD | 97.321% |
| Quoin Pharmaceuticals, Ltd. | 3523.73 USD | -1545.983% |
| Rigel Pharmaceuticals, Inc. | 60.57 Million USD | 99.904% |
| CorMedix Inc. | 667.63 Thousand USD | 91.313% |
| Instil Bio, Inc. | 86.05 Million USD | 99.933% |
| Recursion Pharmaceuticals, Inc. | 50.67 Million USD | 99.886% |
| Contineum Therapeutics, Inc. Class A Common Stock | 193.19 Million USD | 99.97% |
| Finch Therapeutics Group, Inc. | 30.12 Million USD | 99.807% |
| Spero Therapeutics, Inc. | 5.54 Million USD | 98.954% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | 99.563% |
| AbCellera Biologics Inc. | 77.38 Million USD | 99.925% |
| Ocular Therapeutix, Inc. | 83.38 Million USD | 99.93% |
| Surrozen, Inc. | 3.37 Million USD | 98.284% |
| Janux Therapeutics, Inc. | 24.54 Million USD | 99.764% |
| Verona Pharma plc | 51.32 Million USD | 99.887% |
| Terns Pharmaceuticals, Inc. | 603 Thousand USD | 90.381% |
| Vir Biotechnology, Inc. | 124.54 Million USD | 99.953% |
| Evaxion Biotech A/S | 10.86 Million USD | 99.466% |
| Verve Therapeutics, Inc. | 74.9 Million USD | 99.923% |
| Shattuck Labs, Inc. | 4.2 Million USD | 98.62% |
| AlloVir, Inc. | 27.42 Million USD | 99.789% |
| BioVie Inc. | 6.11 Million USD | 99.051% |
| Codexis, Inc. | 22.36 Million USD | 99.741% |
| SELLAS Life Sciences Group, Inc. | 906 Thousand USD | 93.598% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | 64.627% |
| Agenus Inc. | 350.24 Million USD | 99.983% |
| Virax Biolabs Group Limited | 224.3 Thousand USD | 74.142% |
| Lantern Pharma Inc. | 234.47 Thousand USD | 75.263% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | 99.724% |
| eFFECTOR Therapeutics, Inc. | 19.44 Million USD | 99.702% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Celcuity Inc. | 37.44 Million USD | 99.845% |
| Cardiff Oncology, Inc. | 2.14 Million USD | 97.301% |
| Acumen Pharmaceuticals, Inc. | 28.48 Million USD | 99.796% |
| IN8bio, Inc. | 4.89 Million USD | 98.815% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Trevi Therapeutics, Inc. | 1.33 Million USD | 95.665% |
| Lexicon Pharmaceuticals, Inc. | 106.06 Million USD | 99.945% |
| Liquidia Corporation | 3.5 Million USD | 98.344% |
| Quantum-Si incorporated | 15.3 Million USD | 99.621% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | 28.991% |
| Xenon Pharmaceuticals Inc. | 10.9 Million USD | 99.468% |
| Sol-Gel Technologies Ltd. | 1.65 Million USD | 96.491% |
| United Therapeutics Corporation | 700 Million USD | 99.992% |
| Solid Biosciences Inc. | 26.26 Million USD | 99.779% |
| Immuneering Corporation | 4.46 Million USD | 98.7% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | 99.563% |
| uniQure N.V. | 138.4 Million USD | 99.958% |
| Xilio Therapeutics, Inc. | 11.45 Million USD | 99.494% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 85.42 Million USD | 99.932% |
| Longboard Pharmaceuticals, Inc. | 475 Thousand USD | 87.789% |
| PMV Pharmaceuticals, Inc. | 13.28 Million USD | 99.563% |
| Elevai Labs, Inc. Common Stock | 210.48 Thousand USD | 72.445% |
| Cue Biopharma, Inc. | 14.69 Million USD | 99.605% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| ARS Pharmaceuticals, Inc. | 274 Thousand USD | 78.832% |
| Zura Bio Limited | - USD | -Infinity% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Elevation Oncology, Inc. | 30.13 Million USD | 99.808% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | 94.112% |
| Immunome, Inc. | 1.65 Million USD | 96.485% |
| Compass Therapeutics, Inc. | 1.73 Million USD | 96.653% |
| enGene Holdings Inc. Warrants | 9.77 Million USD | 99.407% |
| Inovio Pharmaceuticals, Inc. | 30.2 Million USD | 99.808% |
| LENZ Therapeutics, Inc. | 362 Thousand USD | 83.978% |
| Altimmune, Inc. | 671 Thousand USD | 91.356% |
| Milestone Pharmaceuticals Inc. | 51.77 Million USD | 99.888% |
| Rallybio Corporation | 392 Thousand USD | 85.204% |
| Plus Therapeutics, Inc. | 4.18 Million USD | 98.613% |
| Dianthus Therapeutics, Inc. | 585 Thousand USD | 90.085% |
| Moolec Science SA | 2.64 Million USD | 97.807% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Tourmaline Bio, Inc. | 415 Thousand USD | 86.024% |
| NeurAxis, Inc. | 224.26 Thousand USD | 74.137% |
| Maravai LifeSciences Holdings, Inc. | 610.96 Million USD | 99.991% |
| Lumos Pharma, Inc. | 6.58 Million USD | 99.119% |
| enGene Holdings Inc. Common Stock | 9.77 Million USD | 99.407% |
| 180 Life Sciences Corp. | 1.32 Million USD | 95.606% |
| NKGen Biotech, Inc. Warrants | 19.92 Million USD | 99.709% |
| Opiant Pharmaceuticals, Inc. | 17.08 Million USD | 99.66% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | 96.27% |
| Nutriband Inc. | 241.28 Thousand USD | 75.962% |
| CG Oncology, Inc. Common stock | 826 Thousand USD | 92.978% |
| argenx SE | 20 Million USD | 99.71% |
| Neurogene Inc. | 16.25 Million USD | 99.643% |
| Mirum Pharmaceuticals, Inc. | 308.14 Million USD | 99.981% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CervoMed Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 28.54 Million USD | 99.797% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| AnaptysBio, Inc. | 17.81 Million USD | 99.674% |
| Design Therapeutics, Inc. | 3.05 Million USD | 98.098% |
| Leap Therapeutics, Inc. | 262 Thousand USD | 77.863% |
| Seelos Therapeutics, Inc. | 14.22 Million USD | 99.592% |
| Achilles Therapeutics plc | 4.61 Million USD | 98.743% |
| NeuroSense Therapeutics Ltd. | 142 Thousand USD | 59.155% |
| ORIC Pharmaceuticals, Inc. | 10.21 Million USD | 99.432% |
| Fractyl Health, Inc. Common Stock | 373.72 Million USD | 99.984% |
| Rani Therapeutics Holdings, Inc. | 30.09 Million USD | 99.807% |
| MoonLake Immunotherapeutics | 3.69 Million USD | 98.432% |
| Palisade Bio, Inc. | 369 Thousand USD | 84.282% |
| Beam Therapeutics Inc. | 173.17 Million USD | 99.967% |
| AEON Biopharma, Inc. | 278 Thousand USD | 79.137% |
| Enliven Therapeutics, Inc. | 335 Thousand USD | 82.687% |
| Kiora Pharmaceuticals, Inc. | 106.89 Thousand USD | 45.739% |
| Iovance Biotherapeutics, Inc. | 75.86 Million USD | 99.924% |
| Taysha Gene Therapies, Inc. | 61.1 Million USD | 99.905% |
| Athira Pharma, Inc. | 1.58 Million USD | 96.341% |
| Vaccinex, Inc. | 247 Thousand USD | 76.518% |
| HCW Biologics Inc. | 6.45 Million USD | 99.101% |
| XOMA Corporation | 124.45 Million USD | 99.953% |
| Nektar Therapeutics | 230.4 Million USD | 99.975% |
| Arvinas, Inc. | 3.4 Million USD | 98.294% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | 96.445% |
| Merus N.V. | 12.16 Million USD | 99.523% |
| Omega Therapeutics, Inc. | 128.42 Million USD | 99.955% |
| Quince Therapeutics, Inc. | 13.81 Million USD | 99.58% |
| Rezolute, Inc. | 2.22 Million USD | 97.397% |
| Clene Inc. | 32.16 Million USD | 99.82% |
| Indaptus Therapeutics, Inc. | 175.05 Thousand USD | 66.867% |
| BeyondSpring Inc. | 3.99 Million USD | 98.548% |
| Synlogic, Inc. | 17.27 Million USD | 99.664% |
| Allarity Therapeutics, Inc. | 1.3 Million USD | 95.538% |
| Phio Pharmaceuticals Corp. | 35 Thousand USD | -65.714% |
| Peak Bio, Inc. | 10.72 Million USD | 99.459% |
| Werewolf Therapeutics, Inc. | 51.92 Million USD | 99.888% |
| Krystal Biotech, Inc. | 8.09 Million USD | 99.283% |
| Karyopharm Therapeutics Inc. | 177.01 Million USD | 99.967% |
| SpringWorks Therapeutics, Inc. | 7.05 Million USD | 99.178% |
| Lipella Pharmaceuticals Inc. | 136.59 Thousand USD | 57.538% |
| MannKind Corporation | 382.37 Million USD | 99.985% |
| Ikena Oncology, Inc. | 10.73 Million USD | 99.46% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 409 Thousand USD | 85.819% |
| Gossamer Bio, Inc. | 212.46 Million USD | 99.973% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 174 Thousand USD | 66.667% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | 99.367% |
| Legend Biotech Corporation | 328.67 Million USD | 99.982% |
| Mural Oncology plc | 15 Million USD | 99.614% |
| Biora Therapeutics, Inc. | 47.42 Million USD | 99.878% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 2.1 Million USD | 97.239% |
| Champions Oncology, Inc. | 7.43 Million USD | 99.219% |
| REGENXBIO Inc. | 89.29 Million USD | 99.935% |
| Ensysce Biosciences, Inc. | 854.69 Thousand USD | 93.214% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 552.98 Thousand USD | 89.511% |
| Edgewise Therapeutics, Inc. | 5.41 Million USD | 98.929% |
| Vaxart, Inc. | 26.51 Million USD | 99.781% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 15.65 Million USD | 99.63% |
| Cellectis S.A. | 92.85 Million USD | 99.938% |
| Longeveron Inc. | 2.04 Million USD | 97.158% |
| Repare Therapeutics Inc. | 3.41 Million USD | 98.299% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.996% |
| Inozyme Pharma, Inc. | 46.59 Million USD | 99.876% |
| Revolution Medicines, Inc. | 87.94 Million USD | 99.934% |
| Nymox Pharmaceutical Corporation | 173 Thousand USD | 66.474% |
| Third Harmonic Bio, Inc. | 3.95 Million USD | 98.533% |
| ArriVent BioPharma, Inc. Common Stock | 317 Thousand USD | 81.703% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 175 Thousand USD | 66.857% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.993% |
| Denali Therapeutics Inc. | 52.24 Million USD | 99.889% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 14.4 Million USD | 99.597% |
| Corvus Pharmaceuticals, Inc. | 1.37 Million USD | 95.779% |
| Cingulate Inc. | 3.13 Million USD | 98.15% |
| Passage Bio, Inc. | 26.29 Million USD | 99.779% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.66 Million USD | 99.13% |
| Day One Biopharmaceuticals, Inc. | 408 Thousand USD | 85.784% |
| Oramed Pharmaceuticals Inc. | 894 Thousand USD | 93.512% |
| Revolution Medicines, Inc. Warrant | 87.94 Million USD | 99.934% |
| Scinai Immunotherapeutics Ltd. | 20.56 Million USD | 99.718% |
| Rhythm Pharmaceuticals, Inc. | 1.26 Million USD | 95.397% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 2.45 Million USD | 97.634% |
| Carisma Therapeutics, Inc. | 3.12 Million USD | 98.143% |
| Unicycive Therapeutics, Inc. | 811 Thousand USD | 92.848% |
| OmniAb, Inc. | 25.56 Million USD | 99.773% |
| Anew Medical, Inc. | 1.6 Million USD | 96.386% |
| Fennec Pharmaceuticals Inc. | 29.58 Million USD | 99.804% |
| Lipocine Inc. | 17.16 Thousand USD | -237.877% |
| Lexeo Therapeutics, Inc. Common Stock | 11.63 Million USD | 99.502% |
| Nautilus Biotechnology, Inc. | 34.62 Million USD | 99.833% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | 99.018% |
| G1 Therapeutics, Inc. | 57.17 Million USD | 99.899% |
| Bellerophon Therapeutics, Inc. | 203 Thousand USD | 71.429% |
| Sage Therapeutics, Inc. | 5.16 Million USD | 98.877% |
| Ocugen, Inc. | 6.94 Million USD | 99.164% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 99.589% |
| Q32 Bio Inc. | 1.31 Million USD | 95.599% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 91.369% |
| Alumis Inc. Common Stock | 32.58 Million USD | 99.822% |
| Equillium, Inc. | 824 Thousand USD | 92.961% |
| Kyverna Therapeutics, Inc. | 9.07 Million USD | 99.361% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | 300.8 Thousand USD | 80.718% |
| Galera Therapeutics, Inc. | 152.29 Million USD | 99.962% |
| Evelo Biosciences, Inc. | 51.13 Million USD | 99.887% |
| Comera Life Sciences Holdings, Inc. | 775.04 Thousand USD | 92.517% |
| Dominari Holdings Inc. | 3.02 Million USD | 98.085% |
| Edesa Biotech, Inc. | 94.48 Thousand USD | 38.616% |
| vTv Therapeutics Inc. | 529 Thousand USD | 89.036% |
| Bio-Techne Corporation | 419.53 Million USD | 99.986% |
| Agios Pharmaceuticals, Inc. | 71.99 Million USD | 99.919% |
| Harmony Biosciences Holdings, Inc. | 193.56 Million USD | 99.97% |
| Prelude Therapeutics Incorporated | 16.88 Million USD | 99.657% |
| Candel Therapeutics, Inc. | 22.76 Million USD | 99.745% |
| iTeos Therapeutics, Inc. | 6.05 Million USD | 99.043% |
| Nkarta, Inc. | 88.33 Million USD | 99.934% |
| BioCardia, Inc. | 1.31 Million USD | 95.589% |
| Iterum Therapeutics plc | 19.5 Million USD | 99.703% |